121 148
[13]
Colin P, Koenig P, Ouzzane A, et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009;104:1436 – 40.
[14]
Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A 2007;104:12129 – 34.
[15]
Roupret M, Drouin SJ, Cancel-Tassin G, Comperat E, Larre S, Cusse- not O. Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. J Urol 2012;187:424 – 8.[16]
Rink M, Robinson BD, Green DA, et al. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol 2012;188:398 – 404.[17]
Masson-Lecomte A, Colin P, Bozzini G, et al. Impact of micropapil- lary histological variant on survival after radical nephroureterec- tomy for upper tract urothelial carcinoma. World J Urol 2014;32: 531 – 7.
[18]
Brierley JD, Gospodarowicz MK, Wittekind C. TNM classi fi cation of malignant tumours. ed. 8 Wiley; 2016.[19]
Roscigno M, Cha EK, Rink M, et al. International validation of the prognostic value of subclassi fi cation for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. BJU Int 2012;110:674 – 81.
[20]
Park J, Habuchi T, Arai Y, et al. Reassessment of prognostic heteroge- neity of pT3 renal pelvic urothelial carcinoma: analysis in terms of proposed pT3 subclassi fi cation systems. J Urol 2014;192:1064 – 71.[21]
Lopez-Beltran A, Gasser T, Hartmann A, et al. Tumors of the urinary system. In: World Health Organisation classi fi cations of tumors: pathology and genetics of tumours of the urinary system and male genital organs. IARC Press; 2004.[22]
Soukup V, Capoun O, Cohen D, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organiza- tion grading classi fi cation systems in non-muscle-invasive bladder cancer: a European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel systematic review. Eur Urol 2017;72:801 – 13.[23]
Cowan NC, Turney BW, Taylor NJ, McCarthy CL, Crew JP. Multi- detector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int 2007;99:1363 – 70.[24]
Messer JC, Terrell JD, Herman MP, et al. Multi-institutional valida- tion of the ability of preoperative hydronephrosis to predict ad- vanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol 2013;31:904 – 8.[25]
Hurel S, Roupret M, Seisen T, et al. In fl uence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carci- noma after radical nephroureterectomy. World J Urol 2015;33: 335 – 41.[26]
Messer J, Shariat SF, Brien JC, et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 2011;108:701 – 5.[27]
Rojas CP, Castle SM, Llanos CA, et al. Low biopsy volume in uretero- scopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urol Oncol 2013;31:1696 – 700.
[28]
Clements T, Messer JC, Terrell JD, et al. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at de fi nitive surgical resection. J Endourol 2012;26:398 – 402.[29]
Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 2012;62:100 – 14.[30]
Rink M, Xylinas E, Margulis V, et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical neph- roureterectomy. Eur Urol 2013;63:1082 – 90.[31]
Xylinas E, Kluth LA, Rieken M, et al. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int 2014;114:56 – 61.
[32]
Ya fi FA, Novara G, Shariat SF, et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 2012;110(2 Pt 2):E7 – 13.[33]
Ouzzane A, Colin P, Xylinas E, et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterec- tomy. Eur Urol 2011;60:1258 – 65.
[34]
Chromecki TF, Cha EK, Fajkovic H, et al. The impact of tumor multifocality on outcomes in patients treated with radical neph- roureterectomy. Eur Urol 2012;61:245 – 53.
[35]
Williams AK, Kassouf W, Chin J, et al. Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urol Oncol 2013;31:1161 – 5.[36]
Sundi D, Svatek RS, Margulis V, et al. Upper tract urothelial carci- noma: impact of time to surgery. Urol Oncol 2012;30:266 – 72.
[37]
Gadzinski AJ, Roberts WW, Faerber GJ, Wolf Jr JS. Long-term out- comes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J Endourol 2012;26:566–73.
[38]
Lee JN, Kwon SY, Choi GS, et al. Impact of surgical wait time on oncologic outcomes in upper urinary tract urothelial carcinoma. J Surg Oncol 2014;110:468 – 75.[39]
Berod AA, Colin P, Yates DR, et al. The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study. BJU Int 2012;110(11 Pt C):E1035 – 40.[40]
Martinez-Salamanca JI, Shariat SF, Rodriguez JC, et al. Prognostic role of ECOG performance status in patients with urothelial carci- noma of the upper urinary tract: an international study. BJU Int 2012;109:1155 – 61.[41]
Ehdaie B, Chromecki TF, Lee RK, et al. Obesity adversely impacts disease speci fi c outcomes in patients with upper tract urothelial carcinoma. J Urol 2011;186:66 – 72.[42]
Dalpiaz O, Pichler M, Mannweiler S, et al. Validation of the pre- treatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br J Cancer 2014;110:2531 – 6.[43]
Roscigno M, Brausi M, Heidenreich A, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011;60:776 – 83.[44]
Colin P, Ouzzane A, Yates DR, et al. In fl uence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival. Ann Surg Oncol 2012;19: 3613 – 20.
[45]
Wheat JC, Weizer AZ, Wolf Jr JS, et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterec- tomy. Urol Oncol 2012;30:252–8.
[46]
Redrow GP, Guo CC, Brausi MA, et al. Upper urinary tract carcinoma in situ: current knowledge, future direction. J Urol 2017;197: 287 – 95.[47]
Scarpini S, Roupret M, Renard-Penna R, Camparo P, Cussenot O, Comperat E. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol 2012;30:182 – 7.
[48]
Roupret M, Fromont G, Azzouzi AR, et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005;65:1233 – 7.
[49]
Favaretto RL, Shariat SF, Savage C, et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model forE U R O P E A N U R O L O GY 7 3 ( 2 0 18 ) 111
–
1 2 2
121